Compare IDEXX Laboratories, Inc. (IDXX) vs Manchester United PLC (MANU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Manchester United PLC — how do they compare? IDEXX Laboratories, Inc. trades at $543.91 (market cap $43.58B), while Manchester United PLC trades at $22.29 (market cap $3.87B). The key difference: IDEXX Laboratories, Inc. is far larger — about 11.3× Manchester United PLC's market cap, and Manchester United PLC pays a 1.26% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | MANU | |
|---|---|---|
Market Cap | $43.58B | $3.87B |
Sector | Health | Media |
52-Week High | $766.68 | $23.53 |
52-Week Low | $526.44 | $15.10 |
Enterprise Value | $44.48B | $4.80B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories trades at $552.46, down 2.64% today, with neutral technical signals but strong fundamental performance. The company maintains robust profitability with 24.63% net margins and has beaten earnings expectations for three consecutive quarters. Recent news highlights AI integration in medical devices and upcoming Q2 2026 results on August 4, 2026. The stock shows consistent revenue growth from $3.4B in 2022 to $4.3B in 2025.
Outlook remains positive given earnings momentum and analyst consensus, though elevated valuation ratios (P/E 41.49) pose risks. Key catalysts include Q2 earnings release and continued AI adoption in veterinary diagnostics. Primary risks involve competitive pressures and market volatility affecting premium valuations.
Manchester United (MANU) trades at $22.45, up 0.99% on the day, with a neutral technical signal and mixed earnings performance. The company reported a net loss of $33.02M for 2025, though revenue grew to $666.51M. Recent news highlights progress on a new 100,000-seat stadium and Champions League qualification, which may boost future revenue. The stock's valuation shows a P/S of 4.21 and negative ROE of -6.36%, reflecting profitability challenges amid strategic investments.
The outlook is cautiously optimistic, driven by stadium development and sports performance, but high debt and inconsistent earnings pose risks. Analysts are mixed with 40% buy ratings. Investors should weigh growth initiatives against financial leverage and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →
